David Shaw’s Puma Biotechnology PBYI Stock Holding History

David Shaw’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-28,300	Closed	-$290K	–	4380
2020 Q4	$290K	Hold	28,300	–	–	﹤0.01%	3610
2020 Q3	$286K	Hold	28,300	–	–	﹤0.01%	3468
2020 Q2	$295K	Hold	28,300	–	–	﹤0.01%	3636
2020 Q1	$239K	Sell	28,300 -60,000	-68%	-$583K	﹤0.01%	3575
2019 Q4	$773K	Hold	88,300	–	–	﹤0.01%	3154
2019 Q3	$951K	Buy	+88,300	New	+$954K	﹤0.01%	2858
2018 Q1	–	Sell	-32,500	Closed	-$3.21M	–	3717
2017 Q4	$3.21M	Buy	32,500 +12,500	+63%	+$1.4M	﹤0.01%	1797
2017 Q3	$2.4M	Buy	+20,000	New	+$1.86M	﹤0.01%	1895
2016 Q2	–	Sell	-10,000	Closed	-$294K	–	3481
2016 Q1	$294K	Sell	10,000 -100	-1%	-$4.52K	﹤0.01%	3021
2015 Q4	$792K	Buy	+10,100	New	+$793K	﹤0.01%	2805
2014 Q4	–	Sell	-5,400	Closed	-$1.29M	–	4189
2014 Q3	$1.29M	Buy	+5,400	New	+$1.11M	﹤0.01%	2603

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's PBYI Position: Q2 2026 in Review

David Shaw reduced its Puma Biotechnology (PBYI) stake by 9.9% in Q2 2026, selling an estimated $255K and leaving 316,343 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

David Shaw first reported a position in PBYI in Q2 2013 and has held it in 47 quarters since. The position peaked at $93.6M in Q1 2018. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

David Shaw held 316,343 shares of Puma Biotechnology worth $2.57M as of Q2 2026.
David Shaw sold 34,892 Puma Biotechnology shares in Q2 2026, an estimated $255K.
Puma Biotechnology made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2985 holding.
David Shaw first reported a position in Puma Biotechnology in Q2 2013 and has held it in 47 quarters since.
David Shaw's Puma Biotechnology position peaked at $93.6M in Q1 2018.
160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.